|Assessment Status||Rapid review complete|
|Indication||Indicated in adult patients for the treatment of relapsing forms of multiple sclerosis.|
|Rapid review commissioned||26/09/2016|
|Rapid review outcome||Full Pharmacoeconomic Evaluation Recommended at the Submitted Price|
The HSE has approved reimbursement following confidential price negotiations.
7/03/2018 – The European Medicines Agency (EMA) has recommended the immediate suspension and recall of daclizumab.